Muilu, Paula http://orcid.org/0000-0003-2375-705X
Rantalaiho, Vappu
Kautiainen, Hannu
Virta, Lauri Juhani
Eriksson, Johan Gunnar
Puolakka, Kari
Funding for this research was provided by:
Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (9U050)
Finnish Rheumatology Research Foundation
Tampereen Reumayhdistys
Suomen Kulttuurirahasto (00170718)
Article History
Received: 18 May 2018
Revised: 12 September 2018
Accepted: 20 September 2018
First Online: 26 September 2018
Compliance with ethical standards
:
: Dr. Puolakka, Dr. Virta, Dr. Eriksson, and Mr. Kautiainen have nothing to disclose. Dr. Rantalaiho reports a speaker’s honorarium and a congress trip from Pfizer and a congress trip from Celegen outside the submitted work. Dr. Muilu reports a Congress trip from UCB Pharma and a Congress trip from MSD Finland outside the submitted work.